Addex Therapeutics Ltd
ADXNNASDAQHealthcare● Active
$5.86
+$0.00(+0.00%)
Market Cap$4220665
P/E Ratio—
52W High$12.05
52W Low$5.41
Addex Therapeutics Ltd (ADXN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ADXN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$1.94
Est. -$1.42 · -36.0%
Revenue
$0.00B
Est. $0.00B · +32.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ADXN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 15, 2026 | — | — | — | — | — | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$1.42 | -$1.94 | -36.0% | $0.00B | $0.00B | +32.3% |
| — Q4 FY2025 | Dec 4, 2025 | — | -$1.50 | — | $0.00B | $0.00B | -84.2% |
| ▲ Q2 FY2025 | Jun 20, 2025 | -$4.26 | -$1.33 | +68.8% | — | $0.00B | — |
| ▼ Q2 FY2025 | Apr 7, 2025 | -$1.42 | -$1.63 | -14.7% | $0.00B | $0.00B | -98.9% |
| ▼ Q4 FY2024 | Nov 22, 2024 | -$1.40 | -$2.77 | -97.9% | $0.00B | $0.00B | -58.2% |
| ▼ Q3 FY2024 | Sep 30, 2024 | -$0.01 | -$1.77 | -17600.0% | $0.00B | $0.00B | -50.5% |
| ▼ Q2 FY2024 | Jun 6, 2024 | -$0.44 | -$1.37 | -210.3% | $0.00B | $0.00B | -66.6% |
Q2 FY2026
Jun 15, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$1.94
EPS Est.
-$1.42
EPS Surpr.
-36.0%
Revenue
$0.00B
Q4 FY2025
Dec 4, 2025
EPS Actual
-$1.50
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Jun 20, 2025Beat
EPS Actual
-$1.33
EPS Est.
-$4.26
EPS Surpr.
+68.8%
Revenue
—
Q2 FY2025
Apr 7, 2025Miss
EPS Actual
-$1.63
EPS Est.
-$1.42
EPS Surpr.
-14.7%
Revenue
$0.00B
Q4 FY2024
Nov 22, 2024Miss
EPS Actual
-$2.77
EPS Est.
-$1.40
EPS Surpr.
-97.9%
Revenue
$0.00B
Q3 FY2024
Sep 30, 2024Miss
EPS Actual
-$1.77
EPS Est.
-$0.01
EPS Surpr.
-17600.0%
Revenue
$0.00B
Q2 FY2024
Jun 6, 2024Miss
EPS Actual
-$1.37
EPS Est.
-$0.44
EPS Surpr.
-210.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q3 FY2025 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q2 FY2025 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q1 FY2025 | $-3.75 | $-3.75 | $-3.75 | 1 |
| Q4 FY2024 | $-1.29 | $-1.29 | $-1.29 | 1 |
| Q3 FY2024 | $-1.22 | $-1.22 | $-1.22 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -36.0% | $7.00 | $6.96 | -0.57% |
| — Q4 FY2025 | Dec 4, 2025 | — | $8.99 | $8.38 | -6.79% |
| ▲ Q2 FY2025 | Jun 20, 2025 | +68.8% | $8.48 | $8.46 | -0.24% |
| ▼ Q2 FY2025 | Apr 7, 2025 | -14.7% | $7.43 | $7.16 | -3.63% |
| ▼ Q4 FY2024 | Nov 22, 2024 | -97.9% | $8.11 | $7.53 | -7.15% |
| ▼ Q3 FY2024 | Sep 30, 2024 | -17600.0% | $9.05 | $9.77 | +7.96% |
| ▼ Q2 FY2024 | Jun 6, 2024 | -210.3% | $8.99 | $9.20 | +2.34% |
| ▼ Q2 FY2024 | Apr 18, 2024 | -513.0% | $22.00 | $20.96 | -4.73% |
Q2 FY2026-0.57%
Report Date
Apr 30, 2026
EPS Beat/Miss
-36.0%
Price Before
$7.00
Price After
$6.96
Q4 FY2025-6.79%
Report Date
Dec 4, 2025
EPS Beat/Miss
—
Price Before
$8.99
Price After
$8.38
Q2 FY2025-0.24%
Report Date
Jun 20, 2025
EPS Beat/Miss
+68.8%
Price Before
$8.48
Price After
$8.46
Q2 FY2025-3.63%
Report Date
Apr 7, 2025
EPS Beat/Miss
-14.7%
Price Before
$7.43
Price After
$7.16
Q4 FY2024-7.15%
Report Date
Nov 22, 2024
EPS Beat/Miss
-97.9%
Price Before
$8.11
Price After
$7.53
Q3 FY2024+7.96%
Report Date
Sep 30, 2024
EPS Beat/Miss
-17600.0%
Price Before
$9.05
Price After
$9.77
Q2 FY2024+2.34%
Report Date
Jun 6, 2024
EPS Beat/Miss
-210.3%
Price Before
$8.99
Price After
$9.20
Q2 FY2024-4.73%
Report Date
Apr 18, 2024
EPS Beat/Miss
-513.0%
Price Before
$22.00
Price After
$20.96
Avg Beat Reaction-0.24%
Avg Miss Reaction-0.96%
Beat Rate1 / 8 quarters
Largest Move+7.96% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ADXN ends December
Addex Therapeutics Ltd (ADXN) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-1.94 — missing the analyst consensus of $-1.42 by -36.0%. The next ADXN earnings date is expected around September 1, 2026.
Each quarter, investors track ADXN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ADXN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ADXN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ADXN earnings · 5 questionsAddex Therapeutics Ltd's next earnings report is expected around September 1, 2026. ADXN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ADXN historically reports after market close (AMC).
ADXN earnings datewhen is ADXN earningsADXN next earnings datewhen does ADXN report earningsADXN earnings calendar
▸ Source: FMP · Addex Therapeutics Ltd SEC filings · US GAAP · Addex Therapeutics Ltd SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026